| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jan 17, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Vaughn Victor | Sr. VP Of Sales | Sell | 24,250 | $46.26 | $1,121,749.50 | -56.5% | |
| Jan 17, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 20,000 | $44.98 | $899,500.00 | -61.5% | |
| Jan 17, 2018 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 51,106 | $4.10 | $209,449.80 | -41.2% | |
| Jan 16, 2018 | NBIX Neurocrine Biosciences Inc | Obrien Christopher Flint | Chief Medical Officer | Sell | 1,750 | $79.14 | $138,499.03 | -3.3% | |
| Jan 16, 2018 | LNTH Lantheus Holdings, Inc. | Crowley John W. | CFO | Sell | 3,866 | $23.52 | $90,913.63 | -2.7% | |
| Jan 16, 2018 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 1,625 | $79.12 | $128,563.01 | -2.0% | |
| Jan 16, 2018 | MRK Merck & Co., Inc. | Holston Michael J | EVP, General Counsel | Sell | 12,500 | $61.63 | $770,375.00 | -20.3% | |
| Jan 16, 2018 | MRK Merck & Co., Inc. | Schechter Adam H | EVP &Pres-global Human Health | Sell | 101,602 | $61.63 | $6,261,731.26 | -61.8% | |
| Jan 16, 2018 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 1,625 | $79.12 | $128,574.71 | -1.2% | |
| Jan 16, 2018 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 1,625 | $79.05 | $128,459.50 | -2.1% | |
| Jan 16, 2018 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 3,750 | $78.89 | $295,819.88 | -1.1% | |
| Jan 16, 2018 | MRK Merck & Co., Inc. | Graddick Weir Mirian M | Exe V-p, Hr | Sell | 65,000 | $61.35 | $3,987,800.00 | -16.0% | |
| Jan 12, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Vaughn Victor | Sr. VP Of Sales | Sell | 5,750 | $45.03 | $258,927.68 | -38.1% | |
| Jan 11, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Patrick Gregory S | VP, Chief Financial Officer | Sell | 50,000 | $43.56 | $2,178,145.00 | -47.2% | |
| Jan 11, 2018 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 6,207 | $60.22 | $373,809.13 | -7.7% | |
| Jan 11, 2018 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 2,612 | $4.40 | $11,492.80 | -1.8% | |
| Jan 10, 2018 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | See Remarks | Sell | 21,655 | $22.40 | $485,110.98 | -12.4% | |
| Jan 10, 2018 | COLL Collegium Pharmaceutical, Inc | Fleming Alison B | Chief Technology Officer | Sell | 6,928 | $19.07 | $132,116.96 | -21.2% | |
| Jan 10, 2018 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 28,885 | $40.19 | $1,160,975.41 | -8.6% | |
| Jan 9, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Vaughn Victor | Sr. VP Of Sales | Sell | 15,000 | $42.04 | $630,649.50 | -61.6% | |
| Jan 5, 2018 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 64,683 | $4.40 | $284,631.07 | -31.3% | |
| Jan 4, 2018 | DVAX Dynavax Technologies Corp | Johnson David Louis | Vice President | Sell | 3,092 | $18.60 | $57,511.20 | -39.6% | |
| Jan 3, 2018 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 1,979 | $79.36 | $157,053.44 | -13.1% | |
| Jan 2, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $54.99 | $54,990.00 | -11.1% | |
| Jan 2, 2018 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 128,257 | $4.25 | $545,092.25 | -47.5% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.